Literature DB >> 3349106

Species differences in sensitivity of nucleoside transport in erythrocytes and cultured cells to inhibition by nitrobenzylthioinosine, dipyridamole, dilazep and lidoflazine.

P G Plagemann1, C Woffendin.   

Abstract

Differences in sensitivity of uridine transport in erythrocytes and cultured cells to inhibition by dipyridamole, dilazep and lidoflazine were largely species-specific; uridine transport in human cells, and probably in pig and rabbit cells, was 2-3- and 10-times more sensitive to inhibition by dipyridamole (IC50 approx. 50 nM) and about 10- and 20-times more sensitive to dilazep inhibition (IC50 approx. 5 nM) than transport in mouse and rat cells, respectively. Uridine transport in human erythrocytes and HeLa cells was strongly inhibited by lidoflazine (IC50 10-140 nM), whereas that in both mouse and rat cells was highly resistant (IC50 greater than 10 microM). Superimposed on species-specific differences were some cell type specific differences in sensitivity of nucleoside transport to these inhibitors. Uridine transport in Walker 256 rat carcinoma cells was more resistant to dipyridamole and dilazep than that of other rat cells. Transport in human Hep-2 cells was more resistant to lidoflazine (IC50 2000 nM) than that of human erythrocytes and HeLa cells, whereas it showed similar sensitivity to dilazep and dipyridamole. Uridine transport in Chinese hamster cells was also more resistant to dilazep than that of baby hamster kidney cells. In addition HeLa cells and clones thereof expressed uridine transporters (about 50% each) with difference of about 1000-fold in sensitivity to inhibition by dilazep (IC50 approx. 5 nM and 5 microM, respectively).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349106     DOI: 10.1016/0167-4889(88)90081-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Dilazep, a nucleoside transporter inhibitor, modulates cell cycle progression and DNA synthesis in rat mesangial cells in vitro.

Authors:  T Sakumura; Z Fujii; S Umemoto; T Murakami; Y Kawata; K Fujii; M Minami; K Sasaki; M Matsuzaki
Journal:  Cell Prolif       Date:  2000-02       Impact factor: 6.831

2.  Extracellular formation and uptake of adenosine during skeletal muscle contraction in the rat: role of adenosine transporters.

Authors:  J Lynge; C Juel; Y Hellsten
Journal:  J Physiol       Date:  2001-12-01       Impact factor: 5.182

Review 3.  Extracellular adenine compounds, red blood cells and haemostasis: facts and hypotheses.

Authors:  J Lüthje
Journal:  Blut       Date:  1989-10

4.  Adenosine transport systems on dissociated brain cells from mouse, guinea-pig, and rat.

Authors:  M E Johnston; J D Geiger
Journal:  Neurochem Res       Date:  1990-09       Impact factor: 3.996

5.  Molecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain.

Authors:  A Kiss; K Farah; J Kim; R J Garriock; T A Drysdale; J R Hammond
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

6.  Uptake of purines in Plasmodium falciparum-infected human erythrocytes is mostly mediated by the human equilibrative nucleoside transporter and the human facilitative nucleobase transporter.

Authors:  Neils B Quashie; Lisa C Ranford-Cartwright; Harry P de Koning
Journal:  Malar J       Date:  2010-01-29       Impact factor: 2.979

7.  Differential uptake of [3H]guanosine by nucleoside transporter subtypes in Ehrlich ascites tumour cells.

Authors:  J R Hammond
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

8.  Contribution of the nucleoside transport system to doxorubicin transport in HL60 cells but not in mononuclear cells.

Authors:  K Nagasawa; T Fumihara; N Ohnishi; T Yokoyama
Journal:  Jpn J Cancer Res       Date:  1999-07

9.  Possibility of contribution of nucleoside transport systems to pirarubicin uptake by HL60 cells but not mononuclear cells.

Authors:  K Nagasawa; N Ohnishi; T Yokoyama
Journal:  Jpn J Cancer Res       Date:  1998-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.